In order to optimise outcome to electroconvulsive therapy (ECT), there has been a trend to remifentanil as an adjunct to standard intravenous induction agents. This has allowed a reduction in the dose of anaesthetic agent, and usually an improved response to stimulation. However there have been no previous studies to ascertain whether this improvement is simply as a result of the reduced dose of anaesthetic agent or whether remifentanil itself might possess epileptogenic properties. This retrospective case-controlled study examined ECT outcomes, determined by electroencephalography (EEG) quality analysis, in patients who received ECT with or without remifentanil, where there was no dose reduction in the anaesthetic agent. There were no improvements seen in the measurements of any EEG parameter, including seizure duration. These observations suggest that remifentanil does not possess any intrinsic proconvulsant activity and that any improvement in outcome seen with its use is as a result of dose reduction in the IV anaesthetic agent.
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The successful outcome of electroconvulsive therapy (ECT) depends to a large degree on an appropriate anaesthetic technique, notably the choice and dosage of anaesthetic agent. Conventional ECT treatment is given under general anaesthesia, usually using an intravenous agent. As all intravenous induction agents used in anaesthetic doses demonstrate anticonvulsant properties they act as antagonists to the electrical stimulus attempting to induce an ECT seizure. The result of this 'anaesthetic antagonism' is twofold. The first, and most obvious, is that by antagonising the ECT stimulus, the quality of seizures can be suboptimal, possibly making the treatment less effective. The other, less well appreciated effect is that because a higher level of stimulus may be required to initiate a seizure, there may be an associated increased risk of undesirable adverse effects such as cognitive dysfunction. Therefore, in order to optimise the response to ECT, the dose of IV induction agent must be minimised. In order to reduce the dose of IV induction agent without increasing the risk of awareness, there has been a recent trend to use adjuvant short-acting opioids such as remifentanil.
A previous pilot study by our group 1 suggested that the addition of remifentanil resulted in no improvement in electroencephalography (EEG) quality, and that this was unaffected by either electrode placement or treatment order. The current study includes data from patients who participated in this pilot study, but includes additional patients. Moreover, in the current expanded study patients were able to act as their own controls, and analysis of responses to individual anaesthetic agents was possible. The aim was to determine whether remifentanil exhibited any intrinsic epileptogenic effects that might enhance seizure quality in patients receiving either propofol or thiopentone anaesthesia for ECT. This would help determine whether the improvements in seizure indices seen in previous studies where remifentanil was combined with an IV induction agent were due to a remifentanil-specific effect or simply as a result of the concomitant reduction in the dose of IV induction agent.
Methods
Ethics approval for the study was provided by the Ramsay Hospital Research Ethics Committee (Approval number 175). The medical records of all patients who had received ECT at the institution during the period from 2007 until June 2015 were reviewed. A patient was included if they had received a pair of ECT treatments where all parameters (ECT electrode placement, level of treatment, type and dose of anaesthetic induction agent) were identical with the exception that one of the treatments had incorporated remifentanil as part of the anaesthetic regimen and the other had not. The analysis did not take into account treatment order.
A MECTA Spectrum 5000Q® device (Mecta Corp., Lake Oswego, OR) was used for all ECT treatments. There was no restriction in the use of different types of electrode placement. The types of ECT used throughout the study were either right unilateral ultrabrief, bifrontal brief, or bitemporal brief. EEG recording was performed through two frontalmastoid EEG channels.
The anaesthetic agent used for induction in all cases was either thiopentone (2.5-5 mg/kg) or propofol (1-2 mg/kg). Suxamethonium (0.5 mg/kg) was administered for the purpose of muscle relaxation. If used, remifentanil (1.0 µg/kg) was administered after the induction agent. The decision to use remifentanil as an adjunct to thiopentone or propofol was at the discretion of the treating anaesthetist. No other agents were used apart from supplemental oxygen.
EEG tracings were analysed using measurement of a range of parameters in a scheme that has been previously used 2 .
As well as measurement of seizure duration, the five further parameters that were determined as part of the study were the time to slow wave activity, amplitude, regularity, stereotypy and post-ictal suppression. These terms, which may be unfamiliar, are defined as follows:
Time to slow wave activity-time in seconds until the apparition of slow wave activity in the seizure; amplitude maximal (in mm) for the slow wave phase-the maximum amplitude in the slow wave phase is a measure of the height of the wave; regularity refers to the morphology of the wave that reflects how well the seizure pattern is defined. Stereotypy refers to the progression of the seizure as expected in three different phases: recruitment, slow wave and suppression. Post-ictal suppression is a measure of the intensity and degree of the isoelectric nature of the electrical silence after the seizure. Seizure duration: the duration of the electrical seizure measured from the onset of electrical activity until the point of post-ictal suppression (seconds).
These parameters were rated using a previously developed structured rating scale by a single trained rater (author PCT) who showed inter-rater reliability with authors CL and VG (intraclass correlation ≥0.8 for all items of the rating scale). The rater was blinded to the nature of anaesthetic received.
ECT data were extracted from the clinical records following the selection criteria outlined above. Comparison of treatment pairs was by paired Student's t-test. Statistical significance was set at P<0.05.
Results
Fifty-three patients were identified by retrospective analysis as being suitable for inclusion in the study. Six were rejected as a result of an inability to accurately interpret EEG tracings because of excessive artefact. Therefore a total of 47 patients were included, yielding a total of 62 paired EEG tracings. The average age of these patients was 54.2 ± 14.8 years. Twentyeight patients were female. The majority (61%) received right unilateral ultrabrief pulse ECT, while the remainder received bifrontal brief pulse (31%) or bitemporal brief pulse (8%) ECT. The dose of anaesthetic induction agent used (mean ± standard deviation) for propofol was 86 ± 18 mg and for thiopentone was 170 ± 49 mg.
The ECT parameters are summarised in Table 1 . These suggest that the addition of remifentanil had no clinically important effect either on seizure duration or on any of the five parameters analysed to reflect EEG quality, irrespective of whether propofol or thiopentone was used as the induction agent.
Discussion
This study used analysis of EEG tracings to determine efficacy of treatment. While not as reliable as using outcome studies using either pre-determined rating scales or psychometric testing 3 , analysis of EEG tracings is certainly superior to the simple measurement of the duration of the electrical seizure, which has been widely used in the majority Electroencephalographic analysis in patients undergoing electroconvulsive therapy who received either propofol or thiopentone as IV induction agents. Each received a pair of treatments with identical doses of IV induction agent either with additional remifentanil 1 μg/kg (Remi) or without (Control). of previous work on ECT. While seizure duration is a useful measurement, it is now known that there is no particular association between seizure duration and efficacy.
Remifentanil is a synthetic opioid of the phenylpiperidine group, used to provide profound analgesia in combination with conventional anaesthetic induction or maintenance agents. However, as opioids reduce the requirements for other anaesthetic agents, it has been used over the years as an anaesthetic co-induction agent for ECT, with the aim of reducing the dose of the IV induction drug.
There have been a number of literature reviews examining the epileptogenic properties of opioids 4, 5, 6 . The consensus is that generally they possess neither anti-nor proconvulsant activity. There have, however, been occasional case reports of epileptiform movements associated with remifentanil use 7,8,9, but in most of these cases, it is difficult to determine if the observed movement represented true epilepsy or was simply involuntary muscle movement that can be associated with opioid use. These observations outlined above have raised the question as to whether remifentanil has specific proconvulsant properties that might be capable of 'potentiating' or 'augmenting' ECT process, or whether the findings are simply a result of a concomitant dose reduction of the selected anaesthetic agent. There have been over 20 studies that have examined this question, most of which have been reviewed by Chen 10 . However, despite the large number of investigations that have been performed, only few are helpful in addressing the question of the usefulness of remifentanil in ECT. This is for two reasons: firstly, in almost all cases the only parameter used to determine if remifentanil had any impact on ECT outcome was difference in seizure duration, which has significant limitations when used as the sole measure of ECT efficacy. Secondly, in all but three studies, the addition of remifentanil was accompanied by a concomitant reduction in the dose of induction agent, making it difficult to determine which parameter was responsible for the observed changes. In these studies the initial dose of the induction agent (whether methohexitone, propofol or thiopentone) was substantially reduced, usually in the order of between 25-75%, and such a combination almost universally resulted in a significant prolongation of EEG seizure duration. There have been two previous studies 11, 12 where remifentanil was added to an anaesthetic regimen without any concomitant dose reduction of IV induction agent. Both measured only seizure duration, and there were no differences in either group.
The present study extends and supports the findings of an earlier finding by our group 1 in which a smaller sample was analysed using a different Linear Effects statistical model. In this pilot study, the results suggested that remifentanil addition had no effect on improving EEG parameters, and that this was independent of both electrode placement and treatment order (i.e. whether the treatment with added remifentanil occurred earlier or later in the ECT schedule).
In the current study, which used an expanded sample size and individual analysis of IV induction agent using treatment pairs, we found that the addition of remifentanil without any concomitant reduction in the dose of induction agent, whether thiopentone or propofol, had no beneficial effect either on seizure quality, either in duration or seizure morphology. As the addition of remifentanil had no apparent advantageous effects, but does incur extra cost, the question must be raised as to whether it confers any benefit for ECT anaesthesia?
This study is limited both by its retrospective nature and relatively low sample sizes with no power calculation. However, it has particular and novel strengths. It involved the individual analysis of the two main induction agents currently used in ECT anaesthesia and the use of data from individual patients who underwent identical ECT treatments with or without remifentanil, thus allowing for the use of paired statistical sample analysis. It also involved the assessment of both seizure morphology and duration. While further prospective studies would be needed to validate the observations made, our findings question the role of remifentanil as an adjuvant to other IV induction agents for ECT.
